BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia
Waldenström macroglobulinemia (WM) is a rare, non-Hodgkin lymphoma that remains incurable. Rituximab, an anti-CD20 monoclonal antibody has been the cornerstone of treatment against WM, and its combination with an alkylator, bendamustine, achieves durable remission in treatment-naive patients with sy...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
MDPI AG
2023-04-01
|
| Col·lecció: | Hemato |
| Matèries: | |
| Accés en línia: | https://www.mdpi.com/2673-6357/4/2/12 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|